Autolus Therapeutics plc: Business Overview, Financials & Competitive Analysis
Autolus Therapeutics plc scores 6/10 on the AskCyborg Cyborg Score (Solid). Early commercial success with profitability inflection opportunity, but manufacturing scale-up risk and regulatory timing in new indications require vigilant monitoring. The company reported 2025 revenue of $75 million with 2026 guidance of $120-$135 million, representing 80-129% revenue growth accelerating faster than the 60% historical growth rate. However, the company.
What is Autolus Therapeutics plc's industry? Autolus Therapeutics plc (autolus.com) operates in Biopharmaceutical/Cell Therapy - CAR-T and Engineered T Cell Therapeutics. AskCyborg classifies Autolus Therapeutics plc under Biopharmaceutical/Cell Therapy - CAR-T and Engineered T Cell Therapeutics in its company registry.
Autolus Therapeutics is a commercial-stage biopharmaceutical company developing next-generation T cell therapies for cancer and autoimmune disease. Using proprietary modular T cell programming technologies, the compan...
Cyborg Score thesis
Early commercial success with profitability inflection opportunity, but manufacturing scale-up risk and regulatory timing in new...
Read the full analyst-debate transcript →Get the Latest Autolus Therapeutics plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAutolus Therapeutics plc Overview
Pro stress-test →Autolus Therapeutics is a commercial-stage biopharmaceutical company developing next-generation T cell therapies for cancer and autoimmune disease. Using proprietary modular T cell programming technologies, the company engineers precisely targeted T cell therapies designed to recognize target cells, overcome their defense mechanisms and eliminate them.
Strategic Profile
Pro stress-test →The company achieved a successful US launch of its lead product AUCATZYL with full year 2025 sales well above expectations and more than 60 treatment centers offering the therapy, while establishing reliable, high-quality product delivery with consistent turnaround time. AUCATZYL received regulatory approval from the FDA, EMA and MHRA for adult r/r B-ALL and launched commercially in the US and UK in 2025, positioning Autolus for expansion into autoimmune indications.
Competitive Landscape
Pro stress-test →Autolus competes in the CAR-T therapy space with a marketed therapy (AUCATZYL) and a pipeline of candidates for hematological malignancies, solid tumors and autoimmune diseases. Primary competitors include Juno Therapeutics (Beταgenix), Gilead (Yescarta family), and emerging players in next-generation T cell engineering. The company's differentiation centers on proprietary modular programming technology and favorable safety profile.
Industry Context
Autolus Therapeutics plc operates in Biopharmaceutical/Cell Therapy - CAR-T and Engineered T Cell Therapeutics.
Key facts
Founded: 2014 · Headquarters: London, United Kingdom · Revenue: $75M (2025)